Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1995-2-27
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0031-4005
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
95
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
318
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:7838659-Anti-Inflammatory Agents,
pubmed-meshheading:7838659-Bone Density,
pubmed-meshheading:7838659-Child,
pubmed-meshheading:7838659-Female,
pubmed-meshheading:7838659-Humans,
pubmed-meshheading:7838659-Osteoporosis,
pubmed-meshheading:7838659-Pregnenediones,
pubmed-meshheading:7838659-Rheumatic Diseases,
pubmed-meshheading:7838659-Spinal Diseases
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Deflazacort in pediatric rheumatic diseases needs a frequent follow-up of bone densitometry.
|
| pubmed:publicationType |
Letter,
Case Reports
|